Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Despite Advances, CMML Survival Odds Remain Poor

Leuk Lymphoma; ePub 2016 Nov 23; Guru Murthy, et al

Publish date:: November 30, 2016

People with chronic myelomonocytic leukemia (CMML) have very poor odds of survival, despite advances in biology and therapy, according to a study involving more than 2,200 individuals.

Investigators looked at participants who had CMML that was diagnosed over an 11-year period ending in 2013. Among the results:

Incidence was significantly higher with advancing age.
It was lower in females, blacks, and Asians/Pacific Islanders.
Patients 20-39 years of age survived a median of 25 months; those aged 40-59, 20 months; 60 to 79, 18 months; 80 and older, 11 months.
Overall survival during 2007–2013 was 17 months, vs 14 months during 2003–2006.

Citation:

Guru Murthy G, Dhakal I, Mehta P. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. [Published online ahead of print November 23, 2016]. Leuk Lymphoma. doi:10.1080/10428194.2016.1258700.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Myelodysplastic Syndrome

Second transplant a good salvage option for children with ALL, AML, or MDS,

Genetic analysis highlights value of germline variants in MDS, AML,

Antibody targeting ‘do not eat me’ signals is active in AML, MDS,

Combo proves most effective in HMA-naive, higher-risk MDS,

More abnormal cells linked to poorer ASCT outcomes in MDS,